Jonas Johnson

Dr. Jonas Johnson

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CSCristina Oliveira da Silva
Cristina Oliveira da Silva
Camilla HageCamilla Hage
Camilla Hage
JJJonas Johnson
Jonas Johnson
MBMagnus Bäck
Magnus Bäck
ANAnikó Ilona Nagy
Anikó Ilona Nagy
AMAristomenis Manouras
Aristomenis Manouras
Background/Objectives: To assess the association between moderate N-terminal natriuretic peptide (NT-proBNP) and cardiac alterations and prognosis in septuagenarians without heart failure (HF). Methods: From the STROKESTOP II screening study, 230 individuals aged 75/76 years with NT-proBNP < 900 ng/L were randomly selected. Subjects with persistent atrial fibrillation (AF), more than mild valvular disease, or HF were excluded. Echocardiography was performed. NT-proBNP ≥ 125 ng/L and paroxysmal AF (pAF) on thumb ECG were used as grouping variables. Participants were followed up during a median of 5 years for cardiovascular mortality, HF, AF, and cerebrovascular events. Cox regression analysis was employed for prognostic assessment. Results: Three groups were identified: SR ≥ 125 (n = 94, no pAF and NT-proBNP ≥ 125 ng/L), pAF (n = 77, pAF and NT-proBNP ≥ 125 ng/L), and controls (n = 30, no pAF and NT-proBNP < 125 ng/L). NT-proBNP was not associated with structural (left atrial volume and left ventricular (LV) mass) or functional (E/e’, LV strain) alterations in any group (p > 0.05). Cardiovascular risk factors (HR: 4.6; CI = 1.7–12.3; p = 0.002), but not NT-proBNP (HR: 1.9; CI = 0.7–5.1; p = 0.2), entailed a prognostic value for the composite endpoint of HF, AF, and cardiovascular death. Conclusions: In septuagenarians without HF, modest NT-proBNP elevation was not associated with echocardiographic changes or prognosis

9 December 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JLJuulia Lantto
Juulia Lantto
KFKari Flo
Kari Flo
ÅVÅse Vårtun
Åse Vårtun
CWChristian Widnes
Christian Widnes
JJJonas Johnson
Jonas Johnson
GAGanesh Acharya
Ganesh Acharya
Hypertensive disorders of pregnancy (HDP) remain a leading cause of maternal and perinatal morbidity worldwide, and current screening strategies have limited predictive value in low-risk populations especially for late-onset HDP. This study aimed to develop and internally validate an interpretable machine-learning model for predicting HDP using noninvasive parameters of maternal systemic hemodynamics, endothelial function, and utero-placental and feto-placental blood flow measured in mid-pregnancy. In this cross-sectional cohort, 577 normotensive women underwent impedance cardiography and Doppler ultrasonography at 22 + 0 to 23 + 6 weeks’ gestation. The incidence of HDP was 16.6% (96/577) most (87.5%) occurring at term (≥ 37 weeks), including 73 cases of gestational hypertension (12.6%) and 23 cases of pre-eclampsia (4.0%). An optimized predictive model with seven physiological features was developed using Extreme Gradient Boosting (XGBoost). Hyperparameters were optimized using stratified 10-fold cross-validation maximizing average Precision Recall Area Under the Curve (PR–AUC), and the decision threshold was selected by maximizing the geometric mean of sensitivity and specificity on a separate validation set. On an independent test set ( n = 58; 10 HDP), the model achieved an Area Under the Receiver Operating Curve (ROC–AUC) of 0.82 (95% CI 0.65–0.95) and a PR–AUC of 0.57 (95% CI 0.26–0.84). At the optimized operating point, sensitivity was 70% (95% CI 0.40–1.00), specificity 79% (95% CI 0.67–0.90), precision 41% (95% CI 0.18–0.65), and negative predictive value 93% (95% CI 0.84–1.00). This interpretable, non-invasive mid-gestation model demonstrates strong discrimination and excellent negative predictive value, supporting its integration into routine second-trimester screening for risk stratification without reliance on biochemical markers.